证券代码：300451 证券简称：创业慧康 公告编号：2025-020 创业慧康科技股份有限公司 第八届监事会第十次会议决议公告 本公司及监事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"或"本公司"）第八届监事 会第十次会议的通知于 2025 年 4 月 3 日以邮件、传真等方式向各位监事发出， 并于 2025 年 4 月 14 日在公司三楼会议室以现场会议的方式召开。会议应到监事 3 名，实到监事 3 名。会议的召开及表决符合《中华人民共和国公司法》《创业 慧康科技股份有限公司章程》等有关规定。 经表决，形成如下决议： 一、审议通过了《关于<2024 年度监事会工作报告>的议案》 具体内容详见同日刊登在中国证监会指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）上的《2024 年度监事会工作报告》。 表决结果：赞成 3 票、反对 0 票、弃权 0 票。 本议案尚需提交 2024 年年度股东大会审议。 二、审议通过了《关于<2024 年年度报告及摘要>的议案》 经审核，监事会认为：董事会编制和审核公司 2024 年 ...

证券代码：300451 证券简称：创业慧康 公告编号：2025-010 创业慧康科技股份有限公司 第八届董事会第十四次会议决议公告 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"或"本公司"）第八届董事 会第十四次会议的通知于 2025 年 4 月 3 日以邮件、电话等方式向各位董事发出， 并于 2025 年 4 月 14 日在公司三楼会议室以现场会议的方式召开。会议应到董事 11 名，实到董事 11 名，公司部分监事、高级管理人员列席了会议。会议的召开 及表决符合《中华人民共和国公司法》《创业慧康科技股份有限公司章程》等有 关规定。 此次会议由董事长张吕峥先生主持，参会董事认真审议后，依照有关规定通 过以下几项决议： 一、审议通过了《关于<2024 年度总经理工作报告>的议案》 表决结果：此项议案以 11 票赞同，0 票反对，0 票弃权，议案获得通过。 二、审议通过了《关于<2024 年度董事会工作报告>的议案》 具体内容详见同日刊登在中国证监会指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）上的《2 ...

证券代码：300451 证券简称：创业慧康 公告编号：2025-015 创业慧康科技股份有限公司 关于 2024 年度拟不进行利润分配的专项说明 本公司及董事会全体成员保证公告的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 创业慧康科技股份有限公司（以下简称"公司"）于 2025 年 4 月 14 日召开 第八届董事会第十四次会议和第八届监事会第十次会议，会议审议通过了《关于 2024 年年度利润分配预案的议案》，本议案尚需提交 2024 年年度股东会议审议。 一、公司 2024 年度利润分配预案 公司拟定 2024 年度利润分配预案为：不派发现金红利、不送红股、不以资 本公积金转增股本，未分配利润结转至下一年度。 二、2024 年度拟不进行利润分配的原因 经天健会计师事务所（特殊普通合伙）审计，公司 2024 年度实现净利润 -167,331,308.80 元，其中母公司实现净利润-268,664,827.30 元，加上年初可供未 分配利润 945,567,359.51 元，扣除 2024 年 5 月已实施的 2023 年度利润分配 15,444,264.92 元，公司截至 2024 年 1 ...

Financial Performance - The company's operating revenue for 2024 was approximately ¥1.42 billion, a decrease of 11.96% compared to ¥1.62 billion in 2023[20] - The net profit attributable to shareholders for 2024 was a loss of approximately ¥173.52 million, representing a decline of 572.96% from a profit of ¥36.69 million in 2023[20] - The net cash flow from operating activities decreased by 27.31% to approximately ¥114.73 million in 2024, down from ¥157.84 million in 2023[20] - The total assets at the end of 2024 were approximately ¥5.67 billion, a decrease of 2.11% from ¥5.79 billion at the end of 2023[20] - The net assets attributable to shareholders decreased by 4.05% to approximately ¥4.42 billion at the end of 2024, down from ¥4.61 billion at the end of 2023[20] - The basic earnings per share for 2024 was -¥0.11, a decline of 650.00% compared to ¥0.02 in 2023[20] - The company reported a total of ¥18.54 million in non-recurring gains for 2024, compared to ¥2.69 million in 2023, suggesting an improvement in non-operational income[26] - The company's total revenue for 2024 was 1,326,657,197.95 CNY, a decrease of 10.33% compared to the previous year[108] - Revenue from the medical industry accounts for 93.25% of total revenue, with a year-on-year decrease of 10.33%[105] - The software sales segment generated approximately 562.62 million yuan, down 17.63% from the previous year[105] - The gross profit margin for the medical industry segment was 46.02%, down by 1.92% year-on-year[108] - The company reported a net profit attributable to shareholders of -54,691,586.00 CNY in Q4 2024, compared to a profit of 67,372,775.00 CNY in Q3 2024[106] Market Conditions and Challenges - The company is currently facing extended project bidding and implementation cycles due to market conditions, impacting revenue[4] - The company faced extended delivery cycles and a gradual release of order volumes due to tightened budgets from clients, impacting Q4 performance[106] - The company has not experienced significant adverse changes in its core business and competitive strengths[5] - The company continues to implement its "HuiKang Cloud Strategy," focusing on the integration of AI technology with healthcare services to drive innovation and digital transformation[85] - The company has observed seasonal fluctuations in payment collection and operational performance, with significant seasonal volatility in operational indicators due to evenly distributed costs throughout the year[149] Research and Development - The company’s R&D investment for 2024 amounts to ¥329,754,886.77, representing 23.18% of its operating revenue, an increase from 21.01% in 2023[118] - The number of R&D personnel increased to 1,370 in 2024, a growth of 2.54% compared to 1,336 in 2023, with R&D personnel now accounting for 37.91% of the total workforce[118] - The company completed multiple R&D projects aimed at enhancing product delivery efficiency and quality, with all projects achieving their technical targets[117] - The company aims to improve user experience and data quality through ongoing projects, which are expected to support business expansion and digital transformation[119] - The company is focused on integrating its products with national standards and enhancing its competitive edge in the market through targeted R&D initiatives[119] Strategic Initiatives and Future Outlook - The company plans to continue its market expansion and product development efforts despite current challenges[8] - The company aims to strengthen its position in the smart healthcare sector by implementing the "HuiKang Cloud" strategy and advancing the deployment of cloud-based products[137] - The company aims to deepen the application of artificial intelligence in smart healthcare, focusing on innovative technology upgrades and the development of intelligent medical solutions by 2025[138] - The company will leverage national project experience to enhance the quality of primary healthcare institutions and develop tools for optimizing medical resource allocation, improving fund supervision efficiency[142] - Future guidance indicates a positive outlook for revenue growth, driven by new product launches and market expansion efforts[171] Governance and Compliance - The company has established a value management system and valuation enhancement plan to improve its market value and protect investor rights[154] - The company has developed various governance regulations to ensure compliance with legal requirements and enhance its governance structure[158] - The company has conducted shareholder meetings in accordance with legal regulations, ensuring equal rights for all shareholders, particularly minority shareholders[159] - The company maintains independence from its largest shareholder, with no interference in decision-making or operations, ensuring no harm to the interests of other shareholders[160] - The board of directors and its committees operate in compliance with relevant regulations, with independent directors leading most committees to provide professional opinions[161] Employee and Management Structure - The total number of employees at the end of the reporting period is 3,614, with 2,388 in the parent company and 1,226 in major subsidiaries[191] - The total employee compensation for 2024 is projected to be 228.41 million CNY, accounting for 29.29% of the company's operating costs[192] - The company emphasizes a "people-oriented" talent strategy and develops annual training plans based on departmental needs[193] - The company has a total of 1,801 production personnel, 225 sales personnel, 37 financial personnel, and 181 administrative personnel[191] - The company’s management structure includes a total of 4 senior management personnel, with specific roles outlined[179] Technology and Innovation - The company is committed to exploring innovative solutions in the healthcare sector, aligning with national healthcare reforms and policies[65] - The company has developed a comprehensive smart health solution to support regional health information systems, focusing on full population coverage and integrated health services[51] - The integration of advanced AI technologies in the MedCopilot system provides doctors with diagnostic assistance and quality control, enhancing clinical decision-making[48] - The company has launched a nursing cloud platform that integrates various healthcare services, allowing for quick deployment and access for medical institutions[58] - The company is building an IoT ecosystem for healthcare, focusing on smart applications and operational management services[61]

Group 1 - BsoftGPT successfully integrated with Qizhen Medical Knowledge Base, enabling Chuangye Huikang to launch differentiated smart medical products through a "knowledge-driven + scenario empowerment" strategy [1] - The AI + medical assistant system provides comprehensive intelligent medical support, covering key processes such as pre-consultation, precise triage, report interpretation, and medication guidance [1] - The "Health Zhongshan" platform, based on BsoftGPT and DeepSeek technology, offers intelligent guidance, AI report analysis, and health advice, optimizing the diagnosis and treatment process [1] Group 2 - Chuangye Huikang, in collaboration with Zhejiang University, launched a patient precision screening system that integrates 12 types of clinical data to identify high-risk patients [2] - The APTS system, piloted at Taizhou Enze Medical Center, tracked over 3,000 outpatient cases in one month, recalling over 800 patients needing intervention, improving early diagnosis and treatment rates by 42% [2] Group 3 - A joint AI + medical innovation laboratory was established to focus on the integration of AI technology in clinical settings, enhancing hospital management and clinical decision-making [3] - The laboratory aims to automate the generation of standardized medical documents, improving efficiency in daily medical documentation for doctors [3] Group 4 - Fujian Medical University Affiliated Xiehe Hospital utilized Chuangye Huikang's AI to enhance hospital management and resource utilization efficiency [4] - Wuhan Central Hospital implemented the DeepSeekR1 intelligent platform, improving decision-making efficiency by over 50% in rare disease diagnosis and complication warnings [4] Group 5 - Chuangye Huikang is actively developing the next-generation medical large model, collaborating with Zhejiang University to create a dual-driven medical model that transitions AI from a tool to a clinical decision partner [5] - The company aims to drive equitable healthcare resource distribution through data intelligence and enhance access to safe and efficient smart medical services [5]

关于公司董事减持计划实施完毕的公告 证券代码：300451 证券简称：创业慧康 公告编号：2025-008 创业慧康科技股份有限公司 | 股东 名称 | 股份性质 | 本次减持前持有股份 | | 本次减持后持有股份 | | | --- | --- | --- | --- | --- | --- | | | | 股数（股） | 占总股本 比例（%） | 股数（股） | 占总股本 比例（%） | | 张吕峥 | 合计持有股份 | 29,173,538 | 1.89 | 23,173,538 | 1.50 | | | 其中：无限售条件股份 | 7,293,385 | 0.47 | 1,293,385 | 0.08 | | | 有限售条件股份 | 21,880,153 | 1.42 | 21,880,153 | 1.42 | 二、其他相关说明 董事张吕峥先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 创业慧康科技股份有限公司（以下简称"公司"）于 2025 年 2 月 19 日披露 了《关于董事减持股份计划的预 ...

证券代码：300451 证券简称：创业慧康 创业慧康科技股份有限公司投资者关系活动记录表 编号：2025-002 | 投资者关系活动 | █特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | 中信证券、兴业证券、富国基金、天驷资产、UG Fund、鸿道 | | | 投资、新思哲、浙江国新投资、银华基金、浪石投资、聆泽私 | | | 募、溪牛投资、新活力资本、凯思博投资、白犀资产、沁源投 | | | 资、姚泾河投资、先锋基金、鹏华基金、嘉实基金、博道基金、 | | | 趣时资产、华夏基金、浙商资管、山证资管、开源证券（排名 | | | 不分先后） | | 时间 | 2025 年 2 月 21 日 10:00-11:00，13:30-14:30 | | 地点 | 公司三楼会议室 | | 上市公司接待人 | 董事兼董事会秘书胡燕女士、副总经理余小益先生、研发中心 | | 员姓名 | AI 产品部总监张适可先生 Q&A | | | Q1 ...

Core Viewpoint - Chuangye Huikang has successfully integrated the DeepSeek large model into multiple hospital clients, exploring various medical business scenarios such as intelligent triage, health consultation, report interpretation, and medical record generation [1] Group 1: Company Developments - Chuangye Huikang is committed to a "technology + scenario" dual-driven approach to enhance cooperation with top institutions like Zhejiang University [1] - The company aims to promote the deep integration of AI technologies like DeepSeek with medical services [1] Group 2: Industry Impact - The initiative is expected to assist the healthcare industry in advancing towards a more efficient and precise smart medical phase [1]

创业慧康科技股份有限公司 关于董事减持股份计划的预披露公告 董事张吕峥先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 证券代码：300451 证券简称：创业慧康 公告编号：2025-007 持有本公司 29,173,538 股（占本公司总股本比例 1.88%，占剔除公司回购 专用账户股份后总股本比例 1.89%）的董事张吕峥先生计划自公告之日起十五个 交易日后的 3 个月内（2025 年 3 月 12 日至 2025 年 6 月 11 日）以大宗交易方式 减持本公司股份不超过 600 万股（占剔除公司回购专用账户股份后总股本比例 0.39%）。 通过大宗交易受让上述股份，受让方在受让后六个月内不得减持其所受让的 股份。 创业慧康科技股份有限公司（以下简称"公司"、"本公司"）于近日收到 董事张吕峥先生出具的《关于股份减持计划的告知函》，现将相关事项公告如下： 一、股东的基本情况 1、股东的名称：张吕峥 2、股东持股情况：截至本公告日，张吕峥先生持有本公司 29,173,538 股， 占本公司 ...

证券代码：300451 证券简称：创业慧康 公告编号：2025-006 创业慧康科技股份有限公司 关于持股 5%以上股东减持计划完成的公告 | 股东名称 | 减持方式 | 减持期间 | 减持均价 | 减持股数 | 减持比例 | | --- | --- | --- | --- | --- | --- | | | | | （元/股） | （股） | （%） | | 葛航 | 集中竞价 | 2025.1.13-2025.2.7 | 4.15 | 15,444,200 | 0.999996 | | | | 合计 | | 15,444,200 | 0.999996 | 截至本公告披露日，葛航先生减持股份情况如下： 2、股东本次减持前后持股情况 | 股东 | | 本次减持前持有股份 | | 本次减持后持有股份 | 占总股本 | | --- | --- | --- | --- | --- | --- | | 名称 | 股份性质 | 股数(股) | 占总股本 | 股数(股) | | | | | | 比例（%） | | 比例（%） | | 葛航 | 合计持有股份 | 220,519,182 | 14.28 | 205,074, ...